Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3745623 | 0.87 | ALDH1A1 (0.39) | ALDH1A1TDP1FFAR3TSHR | |
| SCHEMBL4607734 | 0.83 | CES1 (0.39) | ALDH1A1LMNATSHR | |
| SCHEMBL27717726 | 0.82 | CES2 (0.40) | ALDH1A1TDP1LMNAHSD17B10TSHR | |
| SCHEMBL29198006 | 0.81 | ALDH1A1 (0.37) | ALDH1A1FFAR3TSHR | |
| SCHEMBL3596259 | 0.80 | ALDH1A1 (0.36) | ALDH1A1TDP1LMNAHSD17B10FFAR3 | |
| SCHEMBL17309159 | 0.80 | ALDH1A1 (0.36) | ALDH1A1TDP1LMNAHSD17B10FFAR3 | |
| SCHEMBL8616866 | 0.78 | ALDH1A1 (0.35) | ALDH1A1TDP1LMNA | |
| SCHEMBL8789803 | 0.78 | LMNA (0.38) | ALDH1A1TDP1LMNAFFAR3TSHR | |
| SCHEMBL7941633 | 0.77 | ALDH1A1 (0.42) | ALDH1A1TDP1LMNAHSD17B10FFAR3 | |
| SCHEMBL5385556 | 0.77 | ALDH1A1 (0.38) | ALDH1A1TDP1LMNAHSD17B10FFAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4525866-A1 | STABILIZATION OF INTEGRIN INHIBITORS | Pliant Therapeutics, Inc. (US) | 2025-03-26 | — | — | EP | claimed |
| WO-2023225119-A1 | STABILIZATION OF INTEGRIN INHIBITORS | PLIANT THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | WO | claimed |
| EP-3545045-A1 | LOW ODOR WATER-BASED COATING COMPOSITION | Swimc LLC (US) | 2019-10-02 | — | — | EP | claimed |
| WO-2018098302-A1 | LOW ODOR WATER-BASED COATING COMPOSITION | VALSPAR SOURCING, INC. (US) | 2018-05-31 | — | — | WO | claimed |
| US-4476270-A | Process for making high solids acrylic dispersion lacquer | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-10-09 | — | — | US | claimed |
| US-4378445-A | EXTERIOR FINISHES FOR AUTOMOBILES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1983-03-29 | — | — | US | claimed |
| US-20260000620-A1 | ORAL DOSAGE FORMS | AMRYT ENDO INC (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4525866-A1 | STABILIZATION OF INTEGRIN INHIBITORS | Pliant Therapeutics, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| WO-2024243431-A1 | TILDACERFONT COCRYSTAL FORMULATIONS | SPRUCE BIOSCIENCES, INC. (US) | 2024-11-28 | — | — | WO | disclosed |
| WO-2023225119-A1 | STABILIZATION OF INTEGRIN INHIBITORS | PLIANT THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20230072164-A1 | GRANULAR PHARMACEUTICAL PRODUCT FOR ORAL ADMINISTRATION FROM A PRE-FILLED STRAW AND METHOD OF MANUFACTURING SUCH PHARMACEUTICAL PRODUCT | ALTERNO LABS D.O.O. (SI) | 2023-03-09 | — | — | US | disclosed |
| EP-4096642-A1 | GRANULAR PHARMACEUTICAL PRODUCT FOR ORAL ADMINISTRATION FROM A PRE-FILLED STRAW AND METHOD OF MANUFACTURING SUCH PHARMACEUTICAL PRODUCT | Alterno Labs d.o.o. (SI) | 2022-12-07 | — | — | EP | disclosed |
| CN-113164789-A | Composition comprising an encapsulate | 宝洁公司 | 2021-07-23 | — | — | CN | disclosed |
| US-20100284957-A1 | Powder Treated with (Meth)Acrylic-Grafted Silicone Polymer and Product Using the Same | 3M INNOVATIVE PROPERTIES COMPANY | 2010-11-11 | — | — | US | disclosed |
| EP-1814924-A2 | AMPHIPHILIC STAR BLOCK COPOLYMERS | FIRMENICH SA (CH) | 2007-08-08 | — | — | EP | disclosed |
| US-20070160561-A1 | AMPHIPHILIC STAR BLOCK COPOLYMERS | FIRMENICH SA (CH) | 2007-07-12 | — | — | US | disclosed |
| WO-2006038110-A2 | AMPHIPHILIC STAR BLOCK COPOLYMERS | FIRMENICH SA (CH) | 2006-04-13 | — | — | WO | disclosed |
| EP-0797122-B1 | Manufacturing method for toner used in electrophotography | DAINIPPON INK & CHEMICALS (JP) | 2002-11-13 | — | — | EP | disclosed |
| US-5843614-A | Manufacturing method for toner used in electrophotography | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1998-12-01 | — | — | US | disclosed |
| EP-0797122-A1 | Manufacturing method for toner used in electrophotography | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1997-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260000620-A1 | ORAL DOSAGE FORMS | PCTP, TAS2R13, MLEC | ALDH1A1 985/4885TDP1 4199/4885LMNA 3624/4885 |
| US-20070160561-A1 | AMPHIPHILIC STAR BLOCK COPOLYMERS | ABCB4, ABCB7, ABCC5 | ALDH1A1 3042/4885TDP1 3567/4885LMNA 3130/4885 |
| US-20100284957-A1 | Powder Treated with (Meth)Acrylic-Grafted Silicone Polymer and Product Using the Same | MMAB, MGMT, ATM | ALDH1A1 2562/4885TDP1 2946/4885LMNA 4130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.